Q1 EPS Estimate for Lexeo Therapeutics Raised by Analyst

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Research analysts at HC Wainwright raised their Q1 2025 EPS estimates for Lexeo Therapeutics in a report released on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.78) for the quarter, up from their previous forecast of ($0.93). HC Wainwright has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.66) EPS and FY2025 earnings at ($2.95) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09.

Several other research firms have also recently weighed in on LXEO. Leerink Partners decreased their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday, March 24th. Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday. Finally, Royal Bank of Canada dropped their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Lexeo Therapeutics has an average rating of “Buy” and an average target price of $22.80.

Lexeo Therapeutics Stock Down 0.2 %

Lexeo Therapeutics stock opened at $4.10 on Friday. The stock has a market cap of $135.57 million, a PE ratio of -1.30 and a beta of 3.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The stock’s fifty day moving average is $4.05 and its two-hundred day moving average is $6.58. Lexeo Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.50.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in LXEO. Bank of New York Mellon Corp grew its holdings in shares of Lexeo Therapeutics by 5.6% during the fourth quarter. Bank of New York Mellon Corp now owns 50,660 shares of the company’s stock worth $333,000 after buying an additional 2,677 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Lexeo Therapeutics by 30.1% during the fourth quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company’s stock worth $88,000 after purchasing an additional 3,093 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period. Wells Fargo & Company MN grew its position in Lexeo Therapeutics by 49.9% in the 4th quarter. Wells Fargo & Company MN now owns 11,156 shares of the company’s stock valued at $73,000 after buying an additional 3,714 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Lexeo Therapeutics by 19.6% in the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company’s stock valued at $166,000 after buying an additional 4,127 shares during the period. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.